The text starts here.

News Release

February 9th, 2006
For Print (PDF 171KB)

Eisai Agrees To Acquire Severe Chronic Pain Agent PrialtTM For Europe From Elan

Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) and Elan Corporation, plc. of Ireland, (President and CEO: Kelly Martin) announced the conclusion of an agreement for the strategic product acquisition in Europe of Elan's non-opioid severe chronic pain agent PrialtTM (generic name: ziconotide acetate) on February 8th, 2006 (US Eastern time).

Upon consummation of this agreement, Eisai will obtain development, manufacturing and marketing rights for PrialtTM for the European region from Elan. This agreement will come into force on receipt of the necessary approvals from relevant regulatory authorities and the satisfaction of other standard closing conditions.

PrialtTM is a peptide which is the synthetic equivalent of a peptide found in a marine snail. It suppresses pain by selectively blocking N-type calcium channels on nerves. In December 2004, the US FDA approved PrialtTM for the management of severe, chronic pain in patients who require intrathecal analgesia. PrialtTM has been awarded an orphan drug status in the European Union, and was granted a Marketing Authorization through the European Union's Centralized Procedure in February 2005. PrialtTM is the first medicine that was approved in Europe as a non-opioid, intrathecal, severe chronic pain agent.

Based on this strategic product acquisition, Eisai aims to expand the range of products and expand the business territory in Europe. The company believes that PrialtTM will meet the needs of patients with severe chronic pain in Europe and contribute to increase their benefits. Eisai will create a foothold in the company's emerging oncology and critical care franchise.

Corporate Communications Department
Eisai Co., Ltd.
TEL: 81-3-3817-5120

[See the attached for the outline of PrialtTM as a reference]

< Note to editors >

[About PrialtTM]
Product name : PrialtTM 100micro gram/1 mL, PrialtTM 100micro gram/1 mL solution for infusion
PrialtTM 200micro gram/2 mL, PrialtTM 200micro gram/2 mL solution for infusion
PrialtTM 500micro gram/5 mL, PrialtTM 500micro gram/5 mL solution for infusion

Generic name :ziconotide acetate

Indication : Treatment of severe, chronic pain in patients who require intrathecal analgesia

Dosing and Administration :
Ziconotide must be administered as a continuous infusion via an intrathecal catheter, using an external or internally implanted mechanical infusion pump capable of delivering an accurate infusion volume. Initiated at 2.4micro gram/day and titrated on an individual patient basis according to the patient's analgesic response and adverse reactions. Patients should be titrated in dose increments of <= 2.4micro gram/day, up to a maximum dose of 21.6micro gram/day. The recommended interval between dose increases is 48 hours or more.